AGIOS PHARMACEUTICALS, INC. Increase (Decrease) in Other Noncurrent Liabilities
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Increase (Decrease) in Other Noncurrent Liabilities of $150.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-30 was -$11.00K.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-09-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-06-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-03-31 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month |
|---|---|---|---|
| 2026-06-30 | $150.00K 10-Q · filed 2026-07-30 | ||
| 2025-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$790.00K 10-Q · filed 2025-10-30 | |
| 2025-06-30 | -$779.00K 10-Q · filed 2026-07-30 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $0.00 10-Q · filed 2025-07-31 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$157.00K derived: sum of 2 quarters · filed 2024-10-31 | -$2.12M 10-Q · filed 2024-10-31 |
| 2023-06-30 | -$157.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$2.12M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | -$1.97M 10-Q · filed 2024-05-02 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $779.00K derived: sum of 2 quarters · filed 2023-11-02 | $779.00K 10-Q · filed 2023-11-02 |
| 2022-06-30 | $779.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $779.00K 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |